Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Canakinumab for the Treatment of Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis

Trial Status: closed to accrual

This phase II trial evaluates the safety and effectiveness of canakinumab for the treatment of patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post essential thrombocythemia myelofibrosis. Treatment with monoclonal antibodies such as canakinumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.